A phase II study of paclitaxel in chemonaïve patients with recurrent high-grade glioma.

[1]  A. Gregor,et al.  Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial , 1998, Journal of neurology, neurosurgery, and psychiatry.

[2]  M. Berger,et al.  Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Cairncross,et al.  Chemotherapy for brain tumors. , 1998, Oncology.

[4]  E. Arbit,et al.  Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. , 1998, International journal of radiation oncology, biology, physics.

[5]  M. Chamberlain,et al.  Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  O. Witte,et al.  Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. , 1997, Neurosurgery.

[7]  S. Piantadosi,et al.  Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Barbarese,et al.  Evaluation of lipid-coated microbubbles as a delivery vehicle for Taxol in brain tumor therapy. , 1997, Neurosurgery.

[9]  J. Slattery,et al.  Chemotherapy response criteria in malignant glioma , 1997, Neurology.

[10]  M. Berger,et al.  Phase II study of paclitaxel in patients with recurrent malignant glioma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Choy,et al.  Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Chamberlain,et al.  Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  H. Choy,et al.  Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. , 1995, Journal of the National Cancer Institute.

[14]  J. Heimans,et al.  Paclitaxel-induced neuropathy. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[16]  M. Taphoorn,et al.  Paclitaxel (Taxol) concentrations in brain tumor tissue. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  D. Áfra,et al.  Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas , 1994, Neurology.

[18]  P. Burger,et al.  Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. , 1994, Cancer research.

[19]  L. Helson,et al.  A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells , 1993, Anti-cancer drugs.

[20]  D. Nelson,et al.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.

[21]  H. Fine,et al.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[22]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[23]  E. Hall,et al.  Taxol sensitizes human astrocytoma cells to radiation. , 1992, Cancer research.

[24]  R. Donehower,et al.  Taxol: a novel investigational antimicrotubule agent. , 1990, Journal of the National Cancer Institute.

[25]  P. Gutin,et al.  Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. , 1990, International journal of radiation oncology, biology, physics.

[26]  K. Takakura,et al.  Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. , 1997, Neurosurgery.

[27]  S. Ashley,et al.  Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. , 1994, European journal of cancer.

[28]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[29]  E. Hall,et al.  Taxol: a novel radiation sensitizer. , 1992, International journal of radiation oncology, biology, physics.